Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis

Clinical trial NCT05642468 · TERMINATED

Trial details

NCT number: NCT05642468
Sponsor: Albireo, an Ipsen Company
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Primary Sclerosing Cholangitis

Start date: 2023-01-09
Primary completion: 2025-07-10
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.